Complement C3 Facilitates Stratification of Stages of Chronic Hepatitis B and Signifies Development of Acute-on-Chronic Liver Failure in Acute Decompensated Cirrhosis

[1]  Ewa Ostrycharz,et al.  New Insights into the Role of the Complement System in Human Viral Diseases , 2022, Biomolecules.

[2]  Rizwan Ahamed,et al.  Critical Updates on Chronic Hepatitis B Virus Infection in 2021 , 2021, Cureus.

[3]  R. Freeman,et al.  From Child-Pugh to MELD score and beyond: taking a walk down memory lane. , 2021, Annals of hepatology.

[4]  G. Szabo,et al.  Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. , 2021, Journal of hepatology.

[5]  Jun Yu Li,et al.  Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure. , 2021, Journal of hepatology.

[6]  S. Kottilil,et al.  Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression , 2021, International journal of molecular sciences.

[7]  R. Moreau,et al.  Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment , 2020, JHEP reports : innovation in hepatology.

[8]  G. Duraisamy,et al.  Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going? , 2020, Viruses.

[9]  John D Lambris,et al.  Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy , 2020, Clinical Immunology.

[10]  S. Zanlungo,et al.  Complement Component C3 Participates in Early Stages of Niemann–Pick C Mouse Liver Damage , 2020, International journal of molecular sciences.

[11]  J. Kao,et al.  Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy , 2020, Clinical Microbiology Reviews.

[12]  Yu-xian Huang,et al.  Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure , 2020, BMC Gastroenterology.

[13]  L. Risch,et al.  The complement system in liver diseases: Evidence-based approach and therapeutic options☆ , 2019, Journal of translational autoimmunity.

[14]  Y. Chawla,et al.  Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update , 2019, Hepatology International.

[15]  Cinque S. Soto,et al.  Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure , 2018, Proceedings of the National Academy of Sciences.

[16]  Kathryn A Phillips,et al.  Precision Medicine: From Science To Value. , 2018, Health affairs.

[17]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[18]  Jun Yu Li,et al.  Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure , 2017, Gut.

[19]  J. Atkinson,et al.  A C3(H20) recycling pathway is a component of the intracellular complement system , 2017, The Journal of clinical investigation.

[20]  L. Peng,et al.  Complement Factor 3 Could Be an Independent Risk Factor for Mortality in Patients with HBV Related Acute-on-Chronic Liver Failure , 2016, BioMed research international.

[21]  Ashok Choudhury,et al.  Acute-on-chronic liver failure: terminology, mechanisms and management , 2016, Nature Reviews Gastroenterology &Hepatology.

[22]  P. Heeger,et al.  Molecules Great and Small: The Complement System. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[23]  P. Kamath,et al.  Acute-on chronic liver failure. , 2012, Journal of hepatology.

[24]  H. B. Lefton,et al.  Diagnosis and epidemiology of cirrhosis. , 2009, The Medical clinics of North America.

[25]  G. Jung,et al.  Model for end-stage liver disease , 2008, Der Chirurg.

[26]  Zhigang Tian,et al.  Liver: An organ with predominant innate immunity , 2007, Hepatology.

[27]  W. Kim,et al.  The model for end‐stage liver disease (MELD) , 2007, Hepatology.

[28]  P. Gasque,et al.  Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  A. B. Sukhomlinov,et al.  [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.

[30]  Victor Kraft.  The Science of Value , 1981 .